This case study is designed for healthcare professionals, oncologists, researchers, and anyone seeking to deepen their knowledge in the rapidly evolving field of precision oncology. Gain a deeper understanding of the significance of genomic information in shaping therapeutic decisions for managing treatment. Observe how others have navigated through the complexities of tailoring treatments to individual patients based on their unique profiles, optimizing the potential for successful outcomes.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to: 

• Recognize the importance of appropriate staging in EGFR-mutated tumors.
• Consider the possibilities of different approaches in oligometastatic disease.
• Demonstrate the important of multidisciplinary discussion.

• Sofia Vidaurre, MD, Brazil

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.